Zepbound vs. Wegovy Under the $50 Medicare Bridge: Which Should You Choose?
For years, the deciding factor between these two blockbuster weight-loss drugs was price. The Medicare GLP-1 Bridge just erased that difference — both now cost the same flat $50 a month. Here's how to compare them when cost is finally off the table.
By Alex Carter, Medicare benefits specialist · Published July 6, 2026 · Reviewed July 6, 2026
Before July 1, 2026, choosing between Zepbound and Wegovy as a Medicare beneficiary was mostly an exercise in decoding formularies: which drug your plan preferred, which tier it sat on, and what the coinsurance would do to your budget. The Medicare GLP-1 Bridge changed the math completely. Under the Bridge, both drugs — along with oral Wegovy — are available for the same flat $50 monthly copay, no deductible, for beneficiaries who qualify through one of the program's three eligibility doors.
When two medications cost exactly the same, the decision shifts to where it arguably should have been all along: effectiveness, side effects, your other health conditions, and practical fit. This article walks through each of those, using the published clinical evidence — including the one large trial that compared the two drugs head to head.
Two different drugs, not two brands of the same thing
A common misconception is that Zepbound and Wegovy are interchangeable versions of one medicine. They are not.
- Wegovy (Novo Nordisk) is semaglutide — a GLP-1 receptor agonist. It mimics one gut hormone (GLP-1) that slows digestion, reduces appetite, and improves how the body handles blood sugar. It's the same molecule as Ozempic, dosed and approved specifically for chronic weight management.
- Zepbound (Eli Lilly) is tirzepatide — a dual GIP and GLP-1 receptor agonist. It activates two gut-hormone pathways instead of one, which is widely believed to explain its stronger average weight-loss results. It's the same molecule as Mounjaro, approved for weight management.
Both are once-weekly injections with pen devices designed for home use. Wegovy is also available as a daily oral tablet — the first pill in this class approved for weight management — and the Bridge covers the oral form too, which matters if needles are a dealbreaker for you.
Sources: FDA.gov — approved drug information for Wegovy (semaglutide) and Zepbound (tirzepatide); CMS.gov — Medicare GLP-1 Bridge.
Head-to-head: what the evidence shows
For years the two drugs could only be compared across separate trials — Wegovy's STEP program versus Zepbound's SURMOUNT program — which is statistically shaky ground. Then came SURMOUNT-5, a large randomized trial that put the two drugs directly against each other in adults with obesity (without diabetes):
- Participants on tirzepatide (Zepbound) lost on average about 20% of their body weight over 72 weeks.
- Participants on semaglutide (Wegovy) lost on average about 14% over the same period.
That's a meaningful gap on average — but two caveats matter for real-world decisions. First, averages hide enormous individual variation: plenty of people respond better to semaglutide than the average tirzepatide patient, and a minority respond weakly to both. Second, trial participants received the highest tolerated doses with close support; typical results outside trials are usually more modest. Use our weight projection tool to see what different response levels could look like for your starting weight.
| Zepbound (tirzepatide) | Wegovy (semaglutide) | |
|---|---|---|
| Maker | Eli Lilly | Novo Nordisk |
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist |
| How it's taken | Once-weekly injection (KwikPen) | Once-weekly injection or daily oral tablet |
| Avg. weight loss (head-to-head trial) | ~20% at 72 weeks | ~14% at 72 weeks |
| Extra FDA-approved indications | Obstructive sleep apnea (with obesity) | Cardiovascular risk reduction (with heart disease + overweight/obesity) |
| Cost under the Bridge | $50/month flat | $50/month flat |
| Prior authorization | Required (weight-management attestation) | Required (weight-management attestation) |
Trial figures are rounded averages from published results and are illustrative — individual results vary. Discuss expectations with your doctor.
When Wegovy may be the smarter pick anyway
If Zepbound produces more average weight loss at the same price, why would anyone choose Wegovy? Several good reasons:
- You have established heart disease. Wegovy carries an FDA-approved indication for reducing the risk of heart attack, stroke, and cardiovascular death in adults with cardiovascular disease and overweight or obesity — evidence Zepbound does not yet have. For a beneficiary who qualified for the Bridge through the prior heart attack/stroke door, that's a serious point in Wegovy's favor. (Our cardiovascular coverage guide covers this in depth.)
- You want a pill, not an injection. Oral Wegovy is covered under the Bridge. Zepbound has no oral form.
- You've already responded well to semaglutide. If you previously took Ozempic or Wegovy and it worked with tolerable side effects, a known-good response usually beats a theoretical average advantage.
- Tolerability. Both drugs cause similar gastrointestinal side effects — nausea, constipation, diarrhea, vomiting, especially during dose increases — but individuals often tolerate one molecule better than the other. There's no reliable way to predict which; it's discovered by experience.
Conversely, Zepbound has the edge if maximum weight loss is the priority, or if you have obstructive sleep apnea — Zepbound is FDA-approved to treat moderate-to-severe OSA in adults with obesity, and improving OSA can reduce blood-pressure and heart strain on its own.
Adults 65 and over should also weigh senior-specific risks — muscle loss, dehydration, and interactions with other medications — which apply to both drugs. We cover those in our senior side-effects guide.
The practical details under the Bridge
A few program mechanics that apply regardless of which drug you and your doctor choose:
- Same copay, same rules. Both drugs are $50/month flat with no deductible. Note the copay does not count toward your $2,100 Part D out-of-pocket cap — see how the cap interacts with the Bridge.
- Prior authorization is required either way. Your prescriber must attest the drug is for weight management and document how you meet one of the three eligibility doors. The paperwork is drug-specific — switching drugs later generally means a new PA. Our step-by-step application guide walks through it.
- Covered forms matter. The Bridge covers the Zepbound KwikPen and Wegovy in both injectable and oral forms. Manufacturer self-pay channels (such as single-dose vials sold directly to consumers) sit outside the Bridge — don't assume a cash-channel product gets the $50 price.
- No manufacturer coupons. Copay cards and discount coupons can't be combined with the Bridge — federal program rules prohibit it. The $50 is the price.
- The program has an end date. The Bridge runs through December 31, 2027. Whichever drug you start, have a conversation with your doctor about the long-term plan — these medications generally need to be continued to maintain weight loss.
Sources: CMS.gov — Medicare GLP-1 Bridge program page; KFF — analysis of Medicare GLP-1 coverage. Verify current rules with your plan.
How to decide: three questions for your doctor
1. "Which fits my conditions?"
Heart disease history points toward Wegovy's proven cardiovascular benefit; sleep apnea points toward Zepbound's OSA indication. Your health profile — not the average trial result — should drive the choice.
2. "What's my realistic target?"
If a 10–15% loss achieves your health goals, both drugs get you there. Chasing maximum percentage loss only matters if your doctor says you need it.
3. "What if I don't tolerate it?"
Ask up front what the switching process looks like — new prior authorization, dose mapping, and timing — so a rough first month doesn't leave you stuck.
First things first: do you qualify?
The drug comparison only matters if you're eligible for the Bridge. The free check takes about a minute.
Check my eligibility →